Mediera Corp
Mediera Corp maintains a strong liquidity position, with a current ratio of 4.36 and cash and equivalents of 59,569,000 TWD, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.02, suggesting a conservative capital structure with minimal reliance on debt financing. Free cash flow of 27,990,000 TWD further supports its liquidity and financial flexibility. Profitability metrics show a return on equity (ROE) of 3.27% and a return on assets (ROA) of 2.89%, which are below the industry median for Electrical Components & Equipment. The company's operating income of 9,829,000 TWD and net income of 17,357,000 TWD reflect modest profitability, with gross profit of 85,251,000 TWD indicating a relatively healthy margin in its core operations. The company's revenue is concentrated in the Taiwan market, with no disclosed international operations. This geographic concentration may expose the company to local economic and regulatory risks. The business is segmented into prescription drugs, indicated drugs, medical equipment, and food and health products, with no detailed revenue breakdown provided for each segment. Looking ahead, the company's revenue is expected to grow, with the latest actual revenue reported at 279,327,000 TWD. However, the growth trajectory is not explicitly quantified in the outlook. Capital expenditures are minimal, with a negative value of -1,733,000 TWD, suggesting a focus on maintaining rather than expanding operations. Risk factors for Mediera Corp are assessed as low in terms of liquidity and dilution. There are no immediate filing-based liquidity or dilution flags detected. The company's low debt levels and strong cash reserves reduce financial risk. Additionally, the absence of dilution potential and no recent equity issuance suggests a stable capital structure. Recent events include the latest actual EPS of 0.08 TWD and revenue of 279,327,000 TWD, as reported by analysts. No significant filings or transcripts have been disclosed that would indicate major operational or strategic changes in the near term.
Business. Mediera Corp is a Taiwan-based company primarily engaged in medical biotechnology, producing prescription drugs, indicated drugs, medical equipment, and food and health products, while also offering health screening services, mainly operating in the Taiwan market.
Classification. Mediera Corp is classified under the Industrials economic sector, Industrial Goods business sector, and Electrical Components & Equipment industry, with a classification confidence of 0.92.
- Mediera Corp has a strong liquidity position with a current ratio of 4.36 and significant cash reserves.
- The company's profitability is modest, with ROE and ROA below industry medians.
- Revenue is concentrated in the Taiwan market, which may limit diversification and increase local risk exposure.
- The company maintains a conservative capital structure with minimal debt and no immediate dilution risks.
- Growth in revenue is expected, but the pace and drivers are not clearly defined in the available data.
- --
- # RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.